Impax Laboratories, Inc. (NASDAQ:IPXL) Valuation According To Analysts
Los Angeles Capital Management Equity Research has invested 0% in Impax Laboratories Inc (NASDAQ:IPXL). Over the last quarter, shares have performed 0.44%. Market Cap is also the figure use to determine company’s size, as opposed to using sales or total asset figures. Impax Laboratories has a 1-year low of $7.75 and a 1-year high of $35.24. A total of 2.34 million shares exchanged hands as contrast to its average trading volume of 2.11 million shares.
Shares of Impax Laboratories Inc (NASDAQ:IPXL) traded down 1.83% during midday trading on Wednesday, hitting $16.10. The overall volume in the last trading session was 3.49 million shares, versus the average volume of 2.51 million shares. The stock’s market capitalization is 1.15B. Shares are trading 1.81% above their 50-day moving average, and 14.43% below their 200-day moving average.
Impax Laboratories (NASDAQ:IPXL) last announced its quarterly earnings data on Wednesday, May 10th. After $0.18 actual earnings per share reported by Ciena Corporation for the previous quarter, Wall Street now forecasts 61.11% EPS growth. Impax Laboratories had a positive return on equity of 11.34% and a negative net margin of 19.93%. The company had revenue of $184.40 million for the quarter, compared to the consensus estimate of $193.17 million. During the same period past year, the company posted $0.43 earnings per share. The company’s quarterly revenue was down 29.7% compared to the same quarter past year. Nationwide Fund Advsrs holds 0% of its portfolio in Impax Laboratories Inc (NASDAQ:IPXL) for 55,251 shares.
IPXL has been the topic of several other reports. If you are reading this article on another website, it was stolen and republished in violation of United States & worldwide copyright law. RSI measures the speed and change of a stock price to warn investors when a stock’s momentum has carried it too far. (IPXL) is 0.11 while the analysts predicted the EPS of the stock to be 0.13 suggesting the company fell short of the analysts’ expectations. Vanguard Group Inc. increased its stake in shares of Impax Laboratories by 4.6% in the first quarter. Louisiana State Employees Retirement System now owns 30,000 shares of the specialty pharmaceutical company’s stock valued at $380,000 after buying an additional 300 shares during the last quarter. It worsened, as 31 investors sold Impax Laboratories Inc shares while 51 reduced holdings. Paloma Partners Management Co now owns 57,730 shares of the specialty pharmaceutical company’s stock valued at $730,000 after buying an additional 3,156 shares during the last quarter. Municipal Employees Retirement System of MI now owns 15,400 shares of the specialty pharmaceutical company’s stock valued at $365,000 after buying an additional 260 shares during the last quarter. Finally, North Tide Capital LLC increased its stake in shares of Impax Laboratories by 50.0% in the first quarter. North Tide Capital LLC now owns 3,000,000 shares of the specialty pharmaceutical company’s stock valued at $37,950,000 after buying an additional 1,000,000 shares during the last quarter.
IPXL has been the subject of a number of analyst reports. Piper Jaffray Companies lowered shares of Impax Laboratories from a “neutral” rating to an “underweight” rating and set a $7.00 price objective on the stock.in a report on Wednesday, March 1st. They noted that the move was a valuation call. Finally, BMO Capital Markets reaffirmed a “market perform” rating and issued a $18.00 price objective on shares of Impax Laboratories in a research report on Friday, January 13th. Royal Bank of Canada lowered their price objective on shares of Impax Laboratories from $15.00 to $10.00 and set a “sector perform” rating for the company in a research report on Thursday, March 2nd. Deutsche Bank AG set a $15.00 price objective on Impax Laboratories and gave the stock a “buy” rating in a research report on Wednesday, April 5th.
Impax Laboratories, Inc. has a consensus hold rating from 12 Wall Street analysts, and the number of shares now sold short amount to at least 11.06% of shares outstanding. 9 analysts have a Hold rating on the stock, and 1 are giving a Sell recommendation.